These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34962614)

  • 1. Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo.
    Peng H; Ding C; Jiang L; Tang W; Liu Y; Zhao L; Yi Z; Ren H; Li C; He Y; Zheng X; Tang H; Chen Z; Qi Z; Zhao P
    Sci China Life Sci; 2022 Jun; 65(6):1181-1197. PubMed ID: 34962614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.
    Chiba S; Kiso M; Nakajima N; Iida S; Maemura T; Kuroda M; Sato Y; Ito M; Okuda M; Yamada S; Iwatsuki-Horimoto K; Watanabe T; Imai M; Armbrust T; Baric RS; Halfmann PJ; Suzuki T; Kawaoka Y
    mBio; 2021 Feb; 13(1):e0304421. PubMed ID: 35100870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor.
    Miao G; Peng H; Tang H; Liu Y; Zheng X; Liu B; Jiang L; Tang W; He Y; Liu Y; Ren H; Zhao P; Qi Z; Ding C
    J Med Virol; 2022 Oct; 94(10):4809-4819. PubMed ID: 35733297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection.
    Bahl AS; Verma VK; Bhatia J; Arya DS
    Chem Biol Interact; 2022 Nov; 367():110179. PubMed ID: 36113631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.
    Plante KS; Dwivedi V; Plante JA; Fernandez D; Mirchandani D; Bopp N; Aguilar PV; Park JG; Tamayo PP; Delgado J; Shivanna V; Torrelles JB; Martinez-Sobrido L; Matos R; Weaver SC; Sastry KJ; Newman RA
    Biomed Pharmacother; 2021 Jun; 138():111457. PubMed ID: 33721754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
    Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
    Schooley RT; Carlin AF; Beadle JR; Valiaeva N; Zhang XQ; Clark AE; McMillan RE; Leibel SL; McVicar RN; Xie J; Garretson AF; Smith VI; Murphy J; Hostetler KY
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0115521. PubMed ID: 34310217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
    Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
    Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
    Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
    Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
    J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
    Boytz R; Słabicki M; Ramaswamy S; Patten JJ; Zou C; Meng C; Hurst BL; Wang J; Nowak RP; Yang PL; Sattler M; Stone RM; Griffin JD; Gray NS; Gummuluru S; Davey RA; Weisberg E
    J Med Virol; 2023 Jan; 95(1):e28157. PubMed ID: 36117402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms.
    Marín-Palma D; Tabares-Guevara JH; Zapata-Cardona MI; Flórez-Álvarez L; Yepes LM; Rugeles MT; Zapata-Builes W; Hernandez JC; Taborda NA
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34833991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.